EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment

Suz Jack Chan, Lisa K Stamp iD, Gareth J Treharne iD, Janet M Y Cheung, Nicola Dalbeth iD, Rebecca Grainger iD, Simon Stebbings, Carlo A Marra

Arthritis Care & Research · 2025-03 · 77 (3) · 349-358

DOI: 10.1002/acr.25437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 16.10.2024. Verfasst von Suz Jack Chan und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Patient Preference, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Otago Research Grant, Health Research Council of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Little is known about the preferences of people with rheumatoid arthritis (RA) regarding tapering of biologic disease‐modifying antirheumatic drugs (bDMARDs). The aim of this study was to assess the preferences of people with RA in relation to potential treatment‐related benefits and risks of bDMARD tapering and the health care service–related attributes that affect tapering.

Methods

Participants with RA who had experience taking a bDMARD completed an online discrete choice experiment. Participants were asked their preferences when given three hypothetical treatment scenarios in which varying the frequency of treatment might alter their chance of adverse effects, of regaining disease control, and of other health care service–related effects. Preference weights were estimated using a multinomial logit model.

Results

There were 142 complete responses. Reduced dosing frequency of bDMARD treatment had the largest impact on preference (mean 1.0, 95% confidence interval [CI] 0.8–1.2), followed by chance of disease flare (mean 0.7, 95% CI 0.6–0.9). Participants were willing to accept an increased risk of flare between 10.6% (95% CI 3.2–17.9) and 60.6% (95% CI 48.1–72.9) in exchange for benefits associated with tapering bDMARDs. Participants with better quality of life were more likely to choose to remain on current treatment. The predicted uptake of bDMARD tapering was high among people with RA, suggesting bDMARD tapering was a favored option.

Conclusion

For individuals with RA, making decisions about tapering bDMARDs involves considering several factors, with the most important determinants identified as dosing frequency and the risk of disease flare. Understanding patient perspectives of bDMARD tapering may enable physicians to make patient‐focused shared health care decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsPatient PreferenceBiological ProductsChoice BehaviorHumansMaleFemaleMiddle AgedAgedAdultDrug Administration Schedule

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • University of Otago, Dunedin, New Zealand.
  • University of Otago, Christchurch, Christchurch, New Zealand.
  • University of Sydney, Sydney, New South Wales, Australia.
  • The University of Auckland, Auckland, New Zealand.
  • University of Otago, Wellington, Wellington, New Zealand.
  • University of Otago, Dunedin, New Zealand, and Curtin University, Perth, Western Australia, Australia.

ORCID-Profile: Lisa K Stamp, Gareth J Treharne, Nicola Dalbeth, Rebecca Grainger

Förderung

  • University of Otago Research Grant
  • Health Research Council of New Zealand

Zitieren

APA

Chan, S. J., Stamp, L. K., Treharne, G. J., Cheung, J. M. Y., Dalbeth, N., Grainger, R., Stebbings, S., & Marra, C. A. (2025). Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. Arthritis Care & Research, 77(3), 349-358. https://doi.org/10.1002/acr.25437

Vancouver

Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, et al. Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. Arthritis Care & Research. 2025;77(3):349-358. doi:10.1002/acr.25437

BibTeX
@article{Chan2025,
  author = {Chan, Suz Jack and Stamp, Lisa K and Treharne, Gareth J and Cheung, Janet M Y and Dalbeth, Nicola and Grainger, Rebecca and Stebbings, Simon and Marra, Carlo A},
  title = {Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment},
  journal = {Arthritis Care & Research},
  year = {2025},
  volume = {77},
  number = {3},
  pages = {349--358},
  doi = {10.1002/acr.25437}
}
Kostenlos starten →